Neither losartan nor atenolol reduce collagen markers beyond blood pressure reduction in hypertension. A LIFE substudy
نویسندگان
چکیده
منابع مشابه
Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study.
BACKGROUND Electrocardiographic left ventricular hypertrophy (LVH) predicts cardiovascular morbidity and mortality, and regression of ECG LVH may predict improved prognosis in hypertensive patients. However, uncertainty persists as to how best to regress ECG LVH. METHODS AND RESULTS Regression of ECG LVH with losartan versus atenolol therapy was assessed in 9193 hypertensive patients with ECG...
متن کاملCardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
BACKGROUND Blood pressure reduction achieved with beta-blockers and diuretics is the best recorded intervention to date for prevention of cardiovascular morbidity and death in patients with hypertension. Left ventricular hypertrophy (LVH) is a strong independent indicator of risk of cardiovascular morbidity and death. We aimed to establish whether selective blocking of angiotensin II improves L...
متن کامل[Beyond blood pressure reduction in the treatment of arterial hypertension. Clinical implications of the LIFE study].
To date, blood-pressure lowering has been the main therapeutic objective in patients with arterial hypertension, regardless of the drug used, except for drugs selected for accompanying conditions. The LIFE study, carried out in 9,193 high-risk hypertensive patients (with ECG criteria of left ventricular hypertrophy), has shown that a therapeutic regimen based on losartan combined with a thiazid...
متن کاملPulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy.
In the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, the primary composite end point of cardiovascular death, stroke, and myocardial infarction was reduced by losartan versus atenolol in patients with hypertension and left ventricular hypertrophy. The objective of this post hoc analysis was to determine the influence of pulse pressure on outcome. Patients were divid...
متن کاملEffects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.
CONTEXT Drug intervention in placebo-controlled trials has been beneficial in isolated systolic hypertension. OBJECTIVE To test the hypothesis that losartan improves outcome better than atenolol in patients with isolated systolic hypertension and electrocardiographically documented left ventricular hypertrophy (ECG-LVH). DESIGN Double-blind, randomized, parallel-group study conducted in 199...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: American Journal of Hypertension
سال: 2005
ISSN: 0895-7061
DOI: 10.1016/j.amjhyper.2005.03.477